Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

The Asembia AXS25 Summit strives to explore ways to improve patient outcomes, especially for rare and complex diseases.

Conference Connect: Determining the Future of Specialty Pharmacy

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Bridging the Gap Between Strategy and Practice in IDN Partnerships

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

BioNTech, BMS to Co-Design and Co-Commercialize New Antibody Candidate for Various Types of Tumors

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one. 

The Tariff Effect: Greater Supply Chain Prepares for Repercussions 

Podcasts

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

How Recent Executive Orders Impact the Drug Pricing Landscape

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

Mercalis and PharmaCord Officially Merge, Form Valeris

Videos

In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with short-term financial returns.

A Balancing Act

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, explains how GLP-1 therapies’ success can influence future investment strategies in high unmet need areas.

The GLP-1 Effect

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

How to Manage Rising Drug Development Costs

In the first part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, shares the key factors that he believes are propelling a continued rise in projected R&D ROI.  

Commercial Channels